China Pharma Holdings Inc (CPHI) - Net Assets
Based on the latest financial reports, China Pharma Holdings Inc (CPHI) has net assets worth $8.49 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.98 Million) and total liabilities ($7.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of China Pharma Holdings Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.49 Million |
| % of Total Assets | 53.14% |
| Annual Growth Rate | N/A |
| 5-Year Change | -3.21% |
| 10-Year Change | -89.33% |
| Growth Volatility | 41.78 |
China Pharma Holdings Inc - Net Assets Trend (2001–2024)
This chart illustrates how China Pharma Holdings Inc's net assets have evolved over time, based on quarterly financial data. Also explore China Pharma Holdings Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for China Pharma Holdings Inc (2001–2024)
The table below shows the annual net assets of China Pharma Holdings Inc from 2001 to 2024. For live valuation and market cap data, see China Pharma Holdings Inc (CPHI) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.75 Million | +3.93% |
| 2023-12-31 | $7.45 Million | +73.77% |
| 2022-12-31 | $4.29 Million | -28.71% |
| 2021-12-31 | $6.02 Million | -24.82% |
| 2020-12-31 | $8.00 Million | -13.35% |
| 2019-12-31 | $9.24 Million | -69.41% |
| 2018-12-31 | $30.20 Million | -29.89% |
| 2017-12-31 | $43.07 Million | -26.89% |
| 2016-12-31 | $58.91 Million | -18.90% |
| 2015-12-31 | $72.64 Million | -31.63% |
| 2014-12-31 | $106.25 Million | -20.08% |
| 2013-12-31 | $132.94 Million | -10.49% |
| 2012-12-31 | $148.52 Million | +4.23% |
| 2011-12-31 | $142.48 Million | +20.81% |
| 2010-12-31 | $117.94 Million | +30.47% |
| 2009-12-31 | $90.40 Million | +29.38% |
| 2008-12-31 | $69.87 Million | +75.72% |
| 2007-12-31 | $39.76 Million | +90.70% |
| 2006-12-31 | $20.85 Million | +30617.56% |
| 2005-12-31 | $-68.32K | 0.00% |
| 2004-12-31 | $-68.32K | +90.69% |
| 2003-12-31 | $-733.96K | -29.60% |
| 2002-12-31 | $-566.35K | 0.00% |
| 2001-12-31 | $-566.35K | -- |
Equity Component Analysis
This analysis shows how different components contribute to China Pharma Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4121813100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $32.62K | 0.42% |
| Other Comprehensive Income | $11.32 Million | 146.10% |
| Other Components | $40.42 Million | 521.72% |
| Total Equity | $7.75 Million | 100.00% |
China Pharma Holdings Inc Competitors by Market Cap
The table below lists competitors of China Pharma Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ASA International Group PLC
LSE:ASAI
|
$2.32 Million |
|
Thai Polycons Public Company Limited
BK:TPOLY
|
$2.32 Million |
|
Foresight Autonomous Holdings Ltd
TA:FRSX
|
$2.32 Million |
|
Applied DNA Sciences, Inc.
NASDAQ:BNBX
|
$2.32 Million |
|
Pro-Pac Packaging Ltd
AU:PPG
|
$2.31 Million |
|
Femto Technologies Inc.
NASDAQ:FMTO
|
$2.31 Million |
|
N. Leventeris S.A.
AT:LEBEK
|
$2.31 Million |
|
Tri Banyan Tirta Tbk
JK:ALTO
|
$2.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Pharma Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,454,621 to 7,747,904, a change of 293,283 (3.9%).
- Net loss of 4,736,365 reduced equity.
- Other comprehensive income decreased equity by 132,412.
- Other factors increased equity by 5,162,060.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.74 Million | -61.13% |
| Other Comprehensive Income | $-132.41K | -1.71% |
| Other Changes | $5.16 Million | +66.63% |
| Total Change | $- | 3.93% |
Book Value vs Market Value Analysis
This analysis compares China Pharma Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $-199.98 | $0.71 | x |
| 2002-12-31 | $-0.12 | $0.71 | x |
| 2003-12-31 | $-0.16 | $0.71 | x |
| 2004-12-31 | $-0.01 | $0.71 | x |
| 2005-12-31 | $-0.01 | $0.71 | x |
| 2006-12-31 | $4.52 | $0.71 | x |
| 2007-12-31 | $10.67 | $0.71 | x |
| 2008-12-31 | $15.15 | $0.71 | x |
| 2009-12-31 | $19.60 | $0.71 | x |
| 2010-12-31 | $25.57 | $0.71 | x |
| 2011-12-31 | $30.89 | $0.71 | x |
| 2012-12-31 | $32.20 | $0.71 | x |
| 2013-12-31 | $28.82 | $0.71 | x |
| 2014-12-31 | $23.03 | $0.71 | x |
| 2015-12-31 | $15.75 | $0.71 | x |
| 2016-12-31 | $12.77 | $0.71 | x |
| 2017-12-31 | $9.34 | $0.71 | x |
| 2018-12-31 | $6.55 | $0.71 | x |
| 2019-12-31 | $2.00 | $0.71 | x |
| 2020-12-31 | $1.74 | $0.71 | x |
| 2021-12-31 | $1.30 | $0.71 | x |
| 2022-12-31 | $0.82 | $0.71 | x |
| 2023-12-31 | $0.70 | $0.71 | x |
| 2024-12-31 | $0.44 | $0.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Pharma Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -104.58%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.92x
- Recent ROE (-61.13%) is below the historical average (-21.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | -2945.14% | 0.09x | 0.00x | $-1.05 Million |
| 2002 | 0.00% | -2945.14% | 0.09x | 0.00x | $-1.05 Million |
| 2003 | 0.00% | -205.64% | 0.37x | 0.00x | $-152.97K |
| 2004 | 0.00% | -2166.67% | 277.08x | 0.00x | $-497.46K |
| 2005 | 0.00% | -2166.67% | 277.08x | 0.00x | $-497.46K |
| 2006 | 41.18% | 39.31% | 0.77x | 1.37x | $6.50 Million |
| 2007 | 32.24% | 38.63% | 0.76x | 1.10x | $8.84 Million |
| 2008 | 25.52% | 34.99% | 0.68x | 1.08x | $10.85 Million |
| 2009 | 22.38% | 32.79% | 0.61x | 1.12x | $11.19 Million |
| 2010 | 19.85% | 31.48% | 0.56x | 1.12x | $11.62 Million |
| 2011 | 13.52% | 23.74% | 0.52x | 1.10x | $5.02 Million |
| 2012 | 3.11% | 8.47% | 0.33x | 1.10x | $-10.23 Million |
| 2013 | -15.05% | -60.99% | 0.21x | 1.19x | $-33.30 Million |
| 2014 | -24.51% | -117.68% | 0.17x | 1.24x | $-36.67 Million |
| 2015 | -21.21% | -75.70% | 0.21x | 1.34x | $-22.67 Million |
| 2016 | -15.59% | -58.97% | 0.20x | 1.33x | $-15.07 Million |
| 2017 | -44.76% | -145.91% | 0.22x | 1.39x | $-23.58 Million |
| 2018 | -35.60% | -87.18% | 0.27x | 1.50x | $-13.77 Million |
| 2019 | -224.11% | -189.51% | 0.49x | 2.41x | $-21.63 Million |
| 2020 | -35.81% | -26.38% | 0.51x | 2.64x | $-3.67 Million |
| 2021 | -56.49% | -35.26% | 0.43x | 3.76x | $-4.00 Million |
| 2022 | -92.61% | -49.02% | 0.46x | 4.15x | $-4.40 Million |
| 2023 | -41.30% | -43.91% | 0.43x | 2.21x | $-3.82 Million |
| 2024 | -61.13% | -104.58% | 0.30x | 1.92x | $-5.51 Million |
Industry Comparison
This section compares China Pharma Holdings Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $103,487,684
- Average return on equity (ROE) among peers: -40.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Pharma Holdings Inc (CPHI) | $8.49 Million | 0.00% | 0.88x | $2.32 Million |
| Aurora Cannabis Inc (ACB) | $1.62 Million | -9.01% | 0.01x | $201.62 Million |
| Akanda Corp (AKAN) | $26.90 Million | -43.34% | 0.45x | $7.75 Million |
| Akebia Ther (AKBA) | $394.76 Million | -70.84% | 0.95x | $270.56 Million |
| Alkermes Plc (ALKS) | $54.20 Million | -73.99% | 0.03x | $5.83 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.51 Billion |
| Amphastar P (AMPH) | $337.33 Million | 1.34% | 0.35x | $797.20 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-175.94 Million | 0.00% | 0.00x | $3.90 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.00 Million | -54.00% | 0.38x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $2.13 Million | -161.70% | 0.44x | $1.80 Billion |
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more